---
title: "Rare Variant Burden and Polygenic Risk in Breast Cancer: Association with Earlier Diagnosis"
id: "medrxiv-17-rare-variant-burden-complements-polygenic-risk-in-breast-cancer-and-is"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-rare-variant-burden-complements-polygenic-risk-in-breast-cancer-and-is"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.17.26365799v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Rare Variant Burden and Polygenic Risk in Breast Cancer: Association with Earlier Diagnosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-rare-variant-burden-complements-polygenic-risk-in-breast-cancer-and-is
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.17.26365799v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The preprint reports that **rare variant burden** complements **polygenic risk** in evaluating **breast cancer** susceptibility and that increased burden is associated with earlier diagnosis. - Authors are Zimeng Yu (Yale) and Yikai Dong (Emory); the manuscript is available on medRxiv with DOI 10.64898/2026.10.17.26365799 and was posted October 21, 2026. - The article is a clinical preprint and has not undergone peer review; the authors and medRxiv state it should not be used to guide clinical practice. - The medRxiv page lists links to a PDF and to data/code resources, but the page content provided here does not include cohort sizes, statistical outcomes, variant definitions, or analytic methods. - The source did not report specific methodology, effect sizes, confidence intervals, or participant demographics in the content provided. - Unanswered items in the available text include sequencing platforms, variant annotation pipelines, criteria for rare variant burden, construction or validation of any polygenic risk score, and whether the association with earlier diagnosis persisted after adjustment for clinical covariates. - The preprint page shows no posted community reviews, TRiP reviews, automated evaluations, or commentary at the time of capture. - For readers and clinicians: the work merits follow-up reading of the full manuscript and peer review before any clinical translation; the medRxiv record provides author contact information and links to the full PDF and supplementary materials as posted by the authors.
## Clinical Analysis & Structured Key Points
Rare variant burden complements polygenic risk in breast cancer and is associated with earlier diagnosis | medRxiv Skip to main content Rare variant burden complements polygenic risk in breast cancer and is associated with earlier diagnosis View ORCID Profile Zimeng Yu , View ORCID Profile Yikai Dong doi: https://doi.org/10.64898/2026.10.17.26365799 Zimeng Yu 1 Yale University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Zimeng Yu For correspondence: zimeng.yu{at}yale.edu Yikai Dong 2 Emory University Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yikai Dong Abstract Info/History Metrics Data/Code Preview PDF Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Rare variant burden complements polygenic risk in breast cancer and is associated with earlier diagnosis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Rare variant burden complements polygenic risk in breast cancer and is associated with earlier diagnosis Zimeng Yu , Yikai Dong medRxiv 2026.10.17.26365799; doi: https://doi.org/10.64898/2026.10.17.26365799 Share This Article: Copy Citation Tools Rare variant burden complements polygenic risk in breast cancer and is associated with earlier diagnosis Zimeng Yu , Yikai Dong medRxiv 2026.10.17.26365799; doi: https://doi.org/10.64898/2026.10.17.26365799 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (631) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4936) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (668) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1664) Epidemiology (16148) Forensic Medicine (35) Gastroenterology (1232) Genetic and Genomic Medicine (7198) Geriatric Medicine (747) Health Economics (1087) Health Informatics (5212) Health Policy (1454) Health Systems and Quality Improvement (1811) Hematology (597) HIV/AIDS (1369) Infectious Diseases (except HIV/AIDS) (16416) Intensive Care and Critical Care Medicine (1191) Medical Education (689) Medical Ethics (156) Nephrology (738) Neurology (7479) Nursing (374) Nutrition (1112) Obstetrics and Gynecology (1275) Occupational and Environmental Health (1028) Oncology (3704) Ophthalmology (1078) Orthopedics (401) Otolaryngology (462) Pain Medicine (489) Palliative Medicine (142) Pathology (715) Pediatrics (1841) Pharmacology and Therapeutics (747) Primary Care Research (780) Psychiatry and Clinical Psychology (6059) Public and Global Health (9903) Radiology and Imaging (2495) Rehabilitation Medicine and Physical Therapy (1497) Respiratory Medicine (1262) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [RevMed’s pancreatic cancer drug moves toward European approval](https://medichelpline.com/clinical-feed/stat-news-3-stat-revmed-s-pancreatic-cancer-drug-nears-european-approval.md)
- [mRNA cancer vaccine with Keytruda: one melanoma patient’s clinical-trial experience](https://medichelpline.com/clinical-feed/stat-news-1-after-a-melanoma-diagnosis-mrna-cancer-vaccine-delivered-a-patient-hope-and-a.md)
- [Breast pCR Predicts Axillary Clearance After Neoadjuvant Chemotherapy in Early Breast Cancer](https://medichelpline.com/clinical-feed/medrxiv-6-correlation-of-axillary-nodal-with-breast-response-following-neoadjuvant.md)
- [Pope Leo XIV Diagnosed with Lung Adenocarcinoma: Key Insights](https://medichelpline.com/clinical-feed/medical-news-today-0-pope-leo-lung-cancer-diagnosis-what-to-know-about-lung-adenocarcinoma.md)
- [Label-free ML identifies multi-cancer signal in urine and plasma four-metabolite panel](https://medichelpline.com/clinical-feed/medrxiv-20-label-free-machine-learning-detects-a-multi-cancer-signal-in-a-noninvasive.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.